Dr Mathew Garnett

Group Leader, Translational Cancer Genomics laboratory and Genomics of Drug Sensitivity in Cancer Project at the Wellcome Trust Sanger Institute, Cambridge UK
Dr. Mathew Garnett

Dr Mathew Garnett

Group Leader, Translational Cancer Genomics laboratory and Genomics of Drug Sensitivity in Cancer Project at the Wellcome Trust Sanger Institute, Cambridge UK
Back

Biography

Mathew Garnett, PhD leads the Translational Cancer Genomics laboratory and Genomics of Drug Sensitivity in Cancer Project at the Wellcome Trust Sanger Institute, Cambridge UK.  He aims to understand how genetic changes contribute to cancer and to identify molecular biomarkers that will improve the development of new cancer therapies using high-throughput chemical and genetic screens in cancer cell lines and organoids.

Mathew is also a member of the scientific leadership team for Open Targets which aims to use genome scale experiments and analysis to evaluate new therapeutic targets.

After obtaining a BSc in Biochemistry (Hons.) at the University of British Columbia, Canada, Mathew completed his PhD with Prof. Richard Marais at the Institute of Cancer Research (London, UK) on the characterisation of BRAF as a cancer gene.  In 2005 Mathew moved to the laboratory of Prof. Ashok Venkitaraman (Cambridge, UK) for his post-doctoral research, where he discovered a new regulator of cell division.  Mathew joined the Sanger Institute in 2009.

Sessions by Dr Mathew Garnett

Parallel Session 2: Model systems

11:30-12:50
Charter 2 & 3